IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i1d10.1007_s40273-020-00980-w.html
   My bibliography  Save this article

Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

Author

Listed:
  • Ruth A. Lewis

    (North Wales Centre for Primary Care Research, College of Health and Behavioural Sciences, Bangor University)

  • Dyfrig Hughes

    (Bangor University)

  • Alex J. Sutton

    (University of Leicester)

  • Clare Wilkinson

    (North Wales Centre for Primary Care Research, Bangor University)

Abstract

Sequential use of alternative treatments for chronic conditions represents a complex intervention pathway; previous treatment and patient characteristics affect both the choice and effectiveness of subsequent treatments. This paper critically explores the methods for quantitative evidence synthesis of the effectiveness of sequential treatment options within a health technology assessment (HTA) or similar process. It covers methods for developing summary estimates of clinical effectiveness or the clinical inputs for the cost-effectiveness assessment and can encompass any disease condition. A comprehensive review of current approaches is presented, which considers meta-analytic methods for assessing the clinical effectiveness of treatment sequences and decision-analytic modelling approaches used to evaluate the effectiveness of treatment sequences. Estimating the effectiveness of a sequence of treatments is not straightforward or trivial and is severely hampered by the limitations of the evidence base. Randomised controlled trials (RCTs) of sequences were often absent or very limited. In the absence of sufficient RCTs of whole sequences, there is no single best way to evaluate treatment sequences; however, some approaches could be re-used or adapted, sharing ideas across different disease conditions. Each has advantages and disadvantages, and is influenced by the evidence available, extent of treatment sequences (number of treatment lines or permutations), and complexity of the decision problem. Due to the scarcity of data, modelling studies applied simplifying assumptions to data on discrete treatments. A taxonomy for all possible assumptions was developed, providing a unique resource to aid the critique of existing decision-analytic models.

Suggested Citation

  • Ruth A. Lewis & Dyfrig Hughes & Alex J. Sutton & Clare Wilkinson, 2021. "Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions," PharmacoEconomics, Springer, vol. 39(1), pages 25-61, January.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:1:d:10.1007_s40273-020-00980-w
    DOI: 10.1007/s40273-020-00980-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-020-00980-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-020-00980-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Bernd Schweikert & Chiara Malmberg & Örjan Åkerborg & Gayathri Kumar & Debby Nott & Sandeep Kiri & Christophe Sapin & Susanne Hartz, 2020. "Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK," PharmacoEconomics - Open, Springer, vol. 4(4), pages 635-648, December.
    2. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    3. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.
    4. Tanya G. K. Bentley & Karen M. Kuntz & Jeanne S. Ringel, 2010. "Bias Associated with Failing to Incorporate Dependence on Event History in Markov Models," Medical Decision Making, , vol. 30(6), pages 651-660, November.
    5. Jonathan Karnon, 2003. "Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation," Health Economics, John Wiley & Sons, Ltd., vol. 12(10), pages 837-848, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Chris Sampson’s journal round-up for 18th January 2021
      by Chris Sampson in The Academic Health Economists' Blog on 2021-01-18 12:00:03

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    2. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    3. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    4. Olivier Ethgen & Baudouin Standaert, 2012. "Population–versus Cohort–Based Modelling Approaches," PharmacoEconomics, Springer, vol. 30(3), pages 171-181, March.
    5. Matthew J. Glover & Edmund Jones & Katya L. Masconi & Michael J. Sweeting & Simon G. Thompson, 2018. "Discrete Event Simulation for Decision Modeling in Health Care: Lessons from Abdominal Aortic Aneurysm Screening," Medical Decision Making, , vol. 38(4), pages 439-451, May.
    6. L. B. Standfield & T. A. Comans & P. A. Scuffham, 2017. "An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 33-47, January.
    7. John Graves & Shawn Garbett & Zilu Zhou & Jonathan S. Schildcrout & Josh Peterson, 2021. "Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation," Medical Decision Making, , vol. 41(4), pages 453-464, May.
    8. Syed Mohiuddin, 2014. "A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 359-372, August.
    9. Lih-Wen Mau & Jaime M. Preussler & Linda J. Burns & Susan Leppke & Navneet S. Majhail & Christa L. Meyer & Tatenda Mupfudze & Wael Saber & Patricia Steinert & David J. Vanness, 2020. "Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach," PharmacoEconomics, Springer, vol. 38(5), pages 515-526, May.
    10. Heß, Michael (Ed.) & Schlieter, Hannes (Ed.), 2014. "Modellierung im Gesundheitswesen: Tagungsband des Workshops im Rahmen der Modellierung 2014," ICB Research Reports 57, University Duisburg-Essen, Institute for Computer Science and Business Information Systems (ICB).
    11. Annemieke Leunis & W. Redekop & Kees van Montfort & Bob Löwenberg & Carin Uyl-de Groot, 2013. "The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia," PharmacoEconomics, Springer, vol. 31(7), pages 605-621, July.
    12. Ortiz-Barrios, Miguel & Arias-Fonseca, Sebastián & Ishizaka, Alessio & Barbati, Maria & Avendaño-Collante, Betty & Navarro-Jiménez, Eduardo, 2023. "Artificial intelligence and discrete-event simulation for capacity management of intensive care units during the Covid-19 pandemic: A case study," Journal of Business Research, Elsevier, vol. 160(C).
    13. Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 21-41, January.
    14. Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016. "Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community," PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
    15. Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon, 2018. "Model Structuring for Economic Evaluations of New Health Technologies," PharmacoEconomics, Springer, vol. 36(11), pages 1309-1319, November.
    16. Topuz, Kazim & Urban, Timothy L. & Yildirim, Mehmet B., 2024. "A Markovian score model for evaluating provider performance for continuity of care—An explainable analytics approach," European Journal of Operational Research, Elsevier, vol. 317(2), pages 341-351.
    17. Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor, 2018. "Smoking Cessation: A Comparison of Two Model Structures," PharmacoEconomics, Springer, vol. 36(9), pages 1101-1112, September.
    18. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
    19. Hossein Haji Ali Afzali & Jonathan Karnon & Jodi Gray, 2012. "A proposed model for economic evaluations of major depressive disorder," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 501-510, August.
    20. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:1:d:10.1007_s40273-020-00980-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.